Findings of a recently published observational retrospective cohort study point to a need for increased efforts to improve timely completion of the human papillomavirus (HPV) vaccine series among boys.
A congressional fact of life is the dangerous “Christmas tree” bill, which passes with so much on it that many things don’t get the scrutiny they deserve. The 21st Century Cures Act, signed into law by President Obama on December 13, 2016, is such a bill.
The Advisory Committee on Immunization Practices (ACIP) has updated the federal immunization guidelines, including more nuances of the guidelines visually represented on the schedule to enhance clarity.
After a poor matchup to circulating viruses in the 2014-2015 season, the Centers for Disease Control and Prevention (CDC) has released a new vaccine for this year, along with updated administration guidelines.
In June, the Advisory Committee on Immunization Practices (ACIP) declined to recommend that a newly approved serogroup B meningococcal (MenB) vaccine series be used universally in adolescents aged 16 to 18 years, basically leaving the decision up to parents and providers.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices discussed vaccination for serogroup B meningococcal disease (MenB) at its June 2015 meeting and voted its recommendation. What does ACIP’s decision mean for your practice?
The American Academy of Pediatrics has announced the release of the 2015 recommended vaccination schedule for children and adolescents in a recent policy statement from the Academy’s Committee on Infectious Diseases.
States with higher rates of cervical cancer (CA) have significantly lower rates of vaccination against human papillomavirus (HPV), according to data presented at a conference of the American Association for Cancer Research.